Please login to the form below

Not currently logged in
Email:
Password:

GRI

This page shows the latest GRI news and features for those working in and with pharma, biotech and healthcare.

Novo spends $800m to buy biotech and 'glucose responsive insulin' tech

Novo spends $800m to buy biotech and 'glucose responsive insulin' tech

Ziylo could help it stay ahead in key insulin franchise. Novo Nordisk is aiming to develop the world’s first glucose responsive insulin (GRI) by acquiring UK biotech start-up Ziylo.

Latest news

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    TiGenix’ board is backing the takeover deal, which values the company at 520m (around $630m), and two major shareholders - Gri-Cel and Grifols - have already said they will tender their shares.

  • No man is an island

    Perhaps the most high-profile example of these is the Global Reporting Initiative (GRI), which now has 50 pharmaceutical and biotech companies among its 1, 000-plus registered organisations.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics